Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease? Hematol Oncol 2018 Feb;36(1):320-323

Date

04/13/2017

Pubmed ID

28401573

DOI

10.1002/hon.2420

Scopus ID

2-s2.0-85042226412   8 Citations

Abstract

Castleman disease is a rare lymphoproliferative disorder with 2 distinctly defined clinical forms. While multicentric Castleman disease (UCD) poses a potential therapeutic challenge, unicentric variant has historically been considered curable with surgical resection. Hence, little is known to guide management of patients with UCD, refractory to surgical resection and combination chemotherapy. We present a case of a patient, negative for HIV and HHV-8, who had an unsuccessful surgical intervention and no response to radiotherapy and chemotherapy. He had severe paraneoplastic pemphigus and was treated with tocilizumab, an anti-interleukin-6 receptor monoclonal antibody that has demonstrated good response rates in multicentric Castleman disease but demonstrated no clinical response despite 2 months of treatment. Our report is the first to describe a lack of response to tocilizumab in the rare setting of refractory UCD and discuss potential for distinct disease biology.

Author List

Abid MB, Peck R, Abid MA, Al-Sakkaf W, Zhang Y, Dunnill GS, Staines K, Sequeiros IM, Lowry L

Author

Muhammad Bilal Abid MD Assistant Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Antibodies, Monoclonal, Humanized
Castleman Disease
Humans
Male
Middle Aged